Law E, Williams N, Korver D, Bender R, Mitra D, Schaefer G, Nelson LM. Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata. JEACP. 2024 Sep;3(4):1119-31. doi: 10.1002/jvc2.441
Paller AS, Marron SE, Whalley D, Nelson L, Qin S, Chao J, Bansal A, Chuang C, Wang Z. Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family. JEACP. 2024 Mar;3(1):253-7. doi: 10.1002/jvc2.290
Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int. 2019 Feb 4;19(26). doi: 10.1186/s12935-019-0740-2
Thijssen JJJ, Bregantini D. Costly sequential experimentation and project valuation with an application to health technology assessment. J Econ Dyn Control. 2017 Apr 1;77:202-29. doi: 10.1016/j.jedc.2017.01.016